

Chiara Lanzillotta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5690183/publications.pdf>

Version: 2024-02-01

25
papers

909
citations

516215

16
h-index

580395

25
g-index

26
all docs

26
docs citations

26
times ranked

1437
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention. <i>Progress in Neurobiology</i> , 2021, 196, 101892.	2.8	21
2	The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome. <i>Neurotherapeutics</i> , 2021, 18, 340-363.	2.1	12
3	Broad Kinase Inhibition Mitigates Early Neuronal Dysfunction in Tauopathy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1186.	1.8	6
4	Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules. <i>Biomolecules</i> , 2021, 11, 266.	1.8	19
5	Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome. <i>Free Radical Biology and Medicine</i> , 2021, 165, 152-170.	1.3	26
6	High-Fat Diet Leads to Reduced Protein O-GlcNAcylation and Mitochondrial Defects Promoting the Development of Alzheimer's Disease Signatures. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3746.	1.8	17
7	Protein Oxidative Damage in UV-Related Skin Cancer and Dysplastic Lesions Contributes to Neoplastic Promotion and Progression. <i>Cancers</i> , 2020, 12, 110.	1.7	8
8	Proteomics Study of Peripheral Blood Mononuclear Cells in Down Syndrome Children. <i>Antioxidants</i> , 2020, 9, 1112.	2.2	5
9	Cytosolic serine hydroxymethyltransferase controls lung adenocarcinoma cells migratory ability by modulating AMP kinase activity. <i>Cell Death and Disease</i> , 2020, 11, 1012.	2.7	11
10	BVR-A Deficiency Leads to Autophagy Impairment through the Dysregulation of AMPK/mTOR Axis in the Brain: Implications for Neurodegeneration. <i>Antioxidants</i> , 2020, 9, 671.	2.2	17
11	Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. <i>Neurobiology of Disease</i> , 2020, 137, 104772.	2.1	54
12	Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives. <i>CNS Drugs</i> , 2019, 33, 957-969.	2.7	45
13	Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1490-1501.	1.8	29
14	Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome. <i>Redox Biology</i> , 2019, 23, 101162.	3.9	46
15	Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2019, 125, 176-189.	2.1	55
16	Therapeutic potential of rescuing protein O-GlcNAcylation in tau-related pathologies. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1-3.	1.4	15
17	Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 347-359.	1.2	19
18	Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. <i>Translational Neurodegeneration</i> , 2018, 7, 28.	3.6	76

#	ARTICLE	IF	CITATIONS
19	Protein nitration profile of CD3+ lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection. <i>Free Radical Biology and Medicine</i> , 2018, 129, 430-439.	1.3	20
20	Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3309-3321.	1.8	29
21	Oxidative stress, protein modification and Alzheimer disease. <i>Brain Research Bulletin</i> , 2017, 133, 88-96.	1.4	230
22	Identification of changes in neuronal function as a consequence of aging and tauopathic neurodegeneration using a novel and sensitive magnetic resonance imaging approach. <i>Neurobiology of Aging</i> , 2017, 56, 78-86.	1.5	23
23	Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 33-45.	1.4	55
24	Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 359-371.	1.2	35
25	Increased Mammalian Target of Rapamycin Signaling Contributes to the Accumulation of Protein Oxidative Damage in a Mouse Model of Down's Syndrome. <i>Neurodegenerative Diseases</i> , 2016, 16, 62-68.	0.8	35